Tumor growth is associated with profound metabolic and neurochemical alterations, which can lead to the onset of anorexia−cachexia syndrome. Anorexia is defined as the loss of the desire to eat, while ...

The Helsinn Group, a Company focused on building quality cancer care, announces that anamorelin, its novel, once-daily ghrelin receptor agonist significantly increased lean body mass (LBM) compared ...

University of Oklahoma researcher Min Li, Ph.D., is the lead author of a new publication in Cancer Cell about cancer cachexia. Cachexia is a muscle-wasting and fat-loss condition that most often ...

New research from the University of Oklahoma, published today in Cancer Cell, describes for the first time a "triangle regulation theory" of cancer-induced cachexia and anorexia. Cachexia is a ...

Swiss Pharma Group Helsinn seals an alliance with Japanese company Chugai by granting exclusive distribution & licensing rights to commercialize its innovative phase III ghrelin receptor agonist in ...

Cachexia is also called wasting syndrome or anorexia cachexia syndrome. It is a complex problem that is more than a loss of appetite. It involves changes in the way your body uses proteins, ...

DUBLIN--(BUSINESS WIRE)--The "Cancer Anorexia-Cachexia Syndrome Disease - Global Clinical Trials Review, H2, 2020" clinical trials has been added to ResearchAndMarkets.com's offering. "Cancer Anorexia ...

Cancer cachexia is a complex metabolic syndrome characterized by the ongoing loss of skeletal muscle mass, with or without fat loss, that cannot be reversed entirely by conventional nutritional ...

Consistent Improvements in Weight Gain, Lean Body Mass, and Activity were Observed Across Treated Patients including +6.4% Mean Weight Gain at 12 Weeks vs −5.4% Mean Weight Loss on Placebo The Phase 2 ...